Lunai Bioworks Inc. LNAI
1.93
(0.01)
(0.52%)
as of 25 Sep
- Market cap
- $8.8M
- P/E
- 0.0×
Follow LNAI
Growth Flags
show if company had growth for consecutive years
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — |
+8 more quarters Free account |
P/S ratio |
0.00 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(9.92) | — | — | — | |
P/B ratio |
0.00 | — | — | — | |
Price to Tangible BV |
0.00 | — | — | — | |
EV/Sales |
0.00 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(1.47) | — | — | — | |
EV/FCF |
(1.47) | — | — | — | |
Quick Ratio |
0.16 | 0.02 | 0.03 | 0.02 | |
Current Ratio |
0.19 | 0.03 | 0.04 | 0.04 | |
Net Debt/EBITDA |
2.28 | 0.28 | 0.19 | 0.12 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.40 | 0.60 | (0.48) | 0.01 | |
Capex/Depreciation |
0.00 | (0.02) | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
76.08% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
6,800.48% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.62 | 0.92 | 0.88 | 0.74 | |
Share Based Compensation of Revenue |
808.61% | 0.00% | 0.00% | — | |
Graham Net Nets |
(1.54) | — | — | — | |
Graham Number |
64.82 | — | — | — | |
Earnings Yield |
(1,873.48%) | — | — | — | |
Free Cash Flow Yield |
(51.92%) | — | — | — | |
Revenue per Share |
0.01 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.33) | (0.36) | (0.48) | (0.88) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.33) | (0.37) | (0.48) | (0.88) | |
Cash per Share |
1.01 | 0.17 | 0.22 | 0.23 | |
Shareholders Equity per Share |
(3.06) | (4.62) | (4.63) | (10.35) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(3.06) | (4.62) | (4.63) | (10.35) | |
Free Cash Flow |
(1.03) | (1.07) | (1.35) | (1.81) | |
Working Capital |
(15.55) | (19.49) | (18.92) | (28.11) | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
Net Current Asset Value |
(15.68) | (19.70) | (19.20) | (28.53) | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
(12,303.35%) | 0.00% | 0.00% | 0.00% | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Payables |
12.20 | 11.64 | 11.75 | 11.00 | |
Average Assets |
63.79 | 59.00 | 64.40 | 85.68 | |
Average Common Equity |
39.42 | 34.26 | 42.52 | 55.31 |
Columns are period end dates